Clinical Trials Using Anti-GITR Agonistic Monoclonal Antibody BMS-986156

Clinical trials are research studies that involve people. The clinical trials on this list are studying Anti-GITR Agonistic Monoclonal Antibody BMS-986156. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trial 1 of 1
  • BMS-986156, Ipilimumab, and Nivolumab with or without Stereotactic Body Radiation Therapy in Treating Patients with Advanced or Metastatic Lung / Chest or Liver Cancers

    This phase I / II trial studies the side effects and best dose of anti-glucocorticoid-induced tumor necrosis factor receptor (GITR) agonistic monoclonal antibody BMS-986156 (BMS-986156) when given together with ipilimumab and nivolumab with or without stereotactic body radiation therapy and to see how well they work in treating patients with lung / chest or liver cancer that has spread to other places in the body (advanced / metastatic). Immunotherapy with monoclonal antibodies, such as BMS-986156, ipilimumab, and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. It is not yet known whether giving BMS-986156, ipilimumab, and nivolumab with or without stereotactic body radiation therapy will work better in treating patients with lung / chest or liver cancers.
    Location: M D Anderson Cancer Center, Houston, Texas